FDA’s Banner Year for Drug Approvals: Time to Change the Focus
This article was originally published in RPM Report
Executive Summary
FDA is entering a big legislative year with a good story to tell based on 30 new molecular entity approvals. But the level of submissions remains constant—suggesting it may be time to shift the focus from what comes out of FDA to what makes it in.